These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Buried Bumper Syndrome: A common complication of levodopa intestinal infusion for Parkinson disease. Spanaki C; Boura I; Avgoustaki A; Orfanoudaki E; Giannopoulou IA; Giakoumakis E; Chlouverakis G; Athanasakis E; Koulentaki M Parkinsonism Relat Disord; 2021 Apr; 85():59-62. PubMed ID: 33743506 [TBL] [Abstract][Full Text] [Related]
30. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Antonini A; Yegin A; Preda C; Bergmann L; Poewe W; Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993 [TBL] [Abstract][Full Text] [Related]
31. Jejunitis secondary to Duodopa® probe, a different complication. Magaz Martínez M; Martínez Porras JL; Oliva B; Abreu L Rev Esp Enferm Dig; 2016 Dec; 108(12):815-816. PubMed ID: 27931110 [TBL] [Abstract][Full Text] [Related]
32. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838 [TBL] [Abstract][Full Text] [Related]
33. [Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease]. Santos-Garcia D; de Deus T; Lopez-Pazos E; Macias-Arribi M; Llaneza-Gonzalez MA; Echarri-Piudo A; Carpintero P; de la Fuente-Fernandez R Rev Neurol; 2014 Jun; 58(11):505-15. PubMed ID: 24861226 [TBL] [Abstract][Full Text] [Related]
35. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377 [TBL] [Abstract][Full Text] [Related]
36. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication. Salomone G; Marano M; di Biase L; Melgari JM; Di Lazzaro V Parkinsonism Relat Disord; 2015 Sep; 21(9):1124-5. PubMed ID: 26242552 [No Abstract] [Full Text] [Related]
37. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Nyholm D; Klangemo K; Johansson A Eur J Neurol; 2012 Aug; 19(8):1079-85. PubMed ID: 22360705 [TBL] [Abstract][Full Text] [Related]
38. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085 [TBL] [Abstract][Full Text] [Related]
39. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358 [TBL] [Abstract][Full Text] [Related]
40. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease]. Toth A; Nagy H; Wacha J; Bereczki D; Takáts A Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]